US steps up Covid-19 vaccine development as another vaccine candidate starts final phase trial
Skip to main content
  • Home
  • Economy
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
  • Epaper
  • More
    • Subscribe
    • COVID-19
    • Bangladesh
    • Splash
    • Videos
    • Games
    • Long Read
    • Infograph
    • Interviews
    • Offbeat
    • Thoughts
    • Podcast
    • Quiz
    • Tech
    • Archive
    • Trial By Trivia
    • Magazine
    • Supplement
  • বাংলা
The Business Standard

Saturday
August 13, 2022

Sign In
Subscribe
  • Home
  • Economy
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
  • Epaper
  • More
    • Subscribe
    • COVID-19
    • Bangladesh
    • Splash
    • Videos
    • Games
    • Long Read
    • Infograph
    • Interviews
    • Offbeat
    • Thoughts
    • Podcast
    • Quiz
    • Tech
    • Archive
    • Trial By Trivia
    • Magazine
    • Supplement
  • বাংলা
SATURDAY, AUGUST 13, 2022
US steps up Covid-19 vaccine development as another vaccine candidate starts final phase trial

Coronavirus chronicle

UNB/Xinhua
02 September, 2020, 02:20 pm
Last modified: 02 September, 2020, 02:37 pm

Related News

  • Will US-China tensions boil over?
  • Wide-body jet demand humming again as Boeing 787 rejoins the fray
  • US House gives Biden a win with massive bill on climate change, drug prices
  • US inflation outlook brightens as import prices fall, consumer sentiment rises
  • Iran may accept EU proposal to revive nuclear deal if demands met, IRNA reports

US steps up Covid-19 vaccine development as another vaccine candidate starts final phase trial

Safe and effective vaccines will be essential to meet the global need, says Fauci

UNB/Xinhua
02 September, 2020, 02:20 pm
Last modified: 02 September, 2020, 02:37 pm
A screenshot taken from the website of the U.S. National Institutes of Health (NIH) on Sept. 1, 2020 shows the title and photo of its latest publication "Covid-19 Phase 3 Vaccine Trial Begins." Photo: Xinhua via UNB
A screenshot taken from the website of the U.S. National Institutes of Health (NIH) on Sept. 1, 2020 shows the title and photo of its latest publication "Covid-19 Phase 3 Vaccine Trial Begins." Photo: Xinhua via UNB

Researchers in the United States are stepping up efforts to work out an effective Covid-19 vaccine as another vaccine candidate has started phase 3 clinical trial on Monday.

The multi-site clinical trial evaluating an investigational Covid-19 vaccine, known as AZD1222, will enroll approximately 30,000 adult volunteers at 80 sites in the United States to evaluate if the candidate vaccine can prevent Covid-19, said the US National Institutes of Health (NIH).

Participants will be randomly assigned to the investigational vaccine group or the placebo group, and neither the investigators nor the participants will know who is assigned to which group.

After an initial screening, participants will receive two injections of either the investigational vaccine or a saline placebo approximately four weeks apart.

One person will receive a placebo injection for every two people who receive AZD1222, which will result in approximately 20,000 people receiving the investigational vaccine and 10,000 people receiving a placebo.

The trial primarily is designed to determine if AZD1222 can prevent symptomatic Covid-19 after two doses.

The trial also will evaluate if the vaccine candidate can prevent SARS-CoV-2 infection regardless of symptoms and if it can prevent severe Covid-19. It also will assess if the experimental vaccine can reduce the incidence of emergency department visits due to Covid-19, according to the NIH.

Emergency authorisation of Covid-19 vaccines needs great care: WHO

The United Kingdom-based global biopharmaceutical company AstraZeneca is leading the trial as regulatory sponsor. The National Institute of Allergy and Infectious Diseases (NIAID), part of the NIH, and the Biomedical Advanced Research and Development Authority are providing funding support for the trial.

The vaccine candidate uses a non-replicating chimpanzee adenovirus to deliver a SARS-CoV-2 spike protein to induce an immune response, said the NIH.

"Safe and effective vaccines will be essential to meet the global need for widespread protection against Covid-19," said NIAID Director Anthony Fauci.

"Positive results from preclinical research led by NIH scientists supported the rapid development of this vaccine candidate, which has also showed promise in early-stage clinical trials," he said.

The United States has been stepping up research on vaccines, drugs and therapies for Covid-19 as confirmed cases hit over 6,062,000 and fatalities surpassed 184,200 as of Tuesday afternoon, according to a tally by Johns Hopkins University.

Last month, the NIH announced the start of a randomized, controlled clinical trial evaluating the safety and efficacy of a treatment regimen consisting of the antiviral remdesivir plus the immunomodulator interferon beta-1a in Covid-19 patients.

The trial was anticipated to enroll more than 1,000 hospitalized adults with Covid-19 at as many as 100 sites in the United States and abroad.

Another experimental Covid-19 vaccine being developed by the NIAID and American biotechnology company Moderna, known as mRNA-1273, started phase 3 clinical trial in late July to evaluate if it can prevent Covid-19 in adults.

The trial, scheduled to be conducted at US clinical research sites, was expected to enroll approximately 30,000 adult volunteers who do not have Covid-19.

US / Vaccine

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • Customers shop for vegetables at the Central de Abastos Market in Mexico City, Mexico.Photographer: Alejandro Cegarra/Bloomberg
    Latin America led world into high-rate era. now it’s stuck there
  • Foreign Minister Dr AK Abdul Momen Photo: Collected
    Referred Bangladesh as 'heaven' in comparison to other countries: Momen
  • BFIU sought illegal money information from Swiss banks repeatedly: BB
    BFIU sought illegal money information from Swiss banks repeatedly: BB

MOST VIEWED

  • North Korea's leader Kim Jong Un greets health workers and scientists struggling with the coronavirus disease (Covid-19) pandemic during a photo session in Pyongyang, North Korea, in this undated photo released on August 10, 2022 by North Korea's Korean Central News Agency (KCNA). KCNA via REUTERS
    North Korea lifts mask mandate, distancing rules after declaring Covid victory
  • A motorist passes by a mural of frontline workers against coronavirus at RK Puram in New Delhi on July 25. Delhi’s Covid-19 recoveries have outstripped new cases on almost all days this month barring a few exceptions, after ramped-up containment and testing efforts over the past month or so. (Sanchit Khanna / HT Photo)
    Delhi to enforce mask mandate again after spurt in Covid cases
  • A general view of the Centers for Disease Control and Prevention (CDC) headquarters in Atlanta, Georgia September 30, 2014. REUTERS/Tami Chappell
    US CDC no longer recommends students quarantine for Covid-19 exposure
  • In this file photo taken on March 2, 2019, Kim Yo Jong, sister of North Korea's leader Kim Jong Un, attends a wreath-laying ceremony at Ho Chi Minh Mausoleum in Hanoi. Photo: Hindustan Times
    Kim Jong Un's sister warns Seoul of 'retaliation' over Covid
  • North Korean leader Kim Jong Un speaks at a politburo meeting of the Worker's Party on the country's coronavirus disease (COVID-19) outbreak response in this undated photo released by North Korea's Korean Central News Agency (KCNA) on May 21, 2022. KCNA via REUTERS
    North Korea declares victory over Covid, suggests leader Kim had it
  • Workers wearing protective suits arrive to a building under lockdown for compulsory testing, following the coronavirus disease (COVID-19) outbreak in Hong Kong, China January 7, 2022. Photo :Reuters
    Hong Kong cuts Covid quarantine stay for incoming travellers

Related News

  • Will US-China tensions boil over?
  • Wide-body jet demand humming again as Boeing 787 rejoins the fray
  • US House gives Biden a win with massive bill on climate change, drug prices
  • US inflation outlook brightens as import prices fall, consumer sentiment rises
  • Iran may accept EU proposal to revive nuclear deal if demands met, IRNA reports

Features

Toes and talons of Shikra. Photo; Enam Ul Haque

Shikra: A leopard with wings!

9h | Panorama
Photo: Noor-A-Alam

Around the world in 10 days: A chance to taste global cuisines

8h | Food
Lobbyists float ludicrous arguments to prevent tobacco control act amendment

Lobbyists float ludicrous arguments to prevent tobacco control act amendment

10h | Panorama
Will US-China tensions boil over?

Will US-China tensions boil over?

8h | Panorama

More Videos from TBS

Climate crisis a blessing in disguise to them

Climate crisis a blessing in disguise to them

25m | Videos
Growing rice crisis shows how important food self-sufficiency is for Bangladesh

Growing rice crisis shows how important food self-sufficiency is for Bangladesh

1h | Videos
What will happen after global warming?

What will happen after global warming?

3h | Videos
Who will clean 'space garbage'?

Who will clean 'space garbage'?

3h | Videos

Most Read

1
Dollar crisis: BB orders removal of 6 banks’ treasury chiefs 
Banking

Dollar crisis: BB orders removal of 6 banks’ treasury chiefs 

2
Photo: Collected
Transport

Will Tokyo’s traffic model solve Dhaka’s gridlocks?

3
Diesel price hiked by Tk34 per litre, Octane by Tk46
Energy

Diesel price hiked by Tk34 per litre, Octane by Tk46

4
Representational Image. Photo: Collected
Bangladesh

Air passengers should plan extra commute time to airport: DMP

5
Arrest warrant against Habib Group chairman, 4 others 
Crime

Arrest warrant against Habib Group chairman, 4 others 

6
File Photo: State Minister for Power, Energy and Mineral Resources Nasrul Hamid
Energy

All factories to remain closed once a week under rationing system

EMAIL US
[email protected]
FOLLOW US
WHATSAPP
+880 1847416158
The Business Standard
  • About Us
  • Contact us
  • Sitemap
  • Privacy Policy
  • Comment Policy
Copyright © 2022
The Business Standard All rights reserved
Technical Partner: RSI Lab

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - [email protected]

For advertisement- [email protected]